Drug Approval | May 07, 2024
Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility
With this, for all our USFDA facilities, EIRs are in place
With this, for all our USFDA facilities, EIRs are in place
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The facility will manufacture tablets, capsules, and injections for the oncology segment
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
These approvals mark significant progress for Venus Remedies in expanding its market presence
The company will provide comprehensive response to USFDA for the observations
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)